Drug Trial Radar · NCT05682144
ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS I
Last checked: Nov 20, 2026Latest source record: Jul 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
11
Planned (sponsor's estimate)
Start
Apr 12, 2023
Primary completion
Jun 1, 2029
Study completion Jun 1, 2044
Sponsor
- Lead sponsor
- Immusoft of CA, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 12, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A first-in-human study using ISP-001 in patients with Mucopolysaccharidosis Type I Hurler-Scheie and Scheie.
Conditions
- Mucopolysaccharidosis IH/S
- Mucopolysaccharidosis IS
Interventions
Autologous Plasmablasts (B cells)Biological
Autologous plasmablasts (B cells) engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty (SB) transposon system.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events and serious adverse eventsTime frame: 24 Weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
UCSF Benioff Children's Hospital Oakland
Oakland, California · Recruiting
University of Minnesota
Minneapolis, Minnesota · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.